AZD4635

AZD-4635, also known as HTL-1071, is an orally available, small molecule adenosine A2A receptor antagonist.

Product information

CAS Number: 1321514-06-0

Molecular Weight: 315.73

Formula: C15H11ClFN5

Synonym:

imaradenant

AZD-4635

HTL-1071

Chemical Name: 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1, 2, 4-triazin-3-amine

Smiles: CC1=CC(=CC(Cl)=N1)C1=NN=C(N)N=C1C1C=CC(F)=CC=1

InChiKey: NCWQLHHDGDXIJN-UHFFFAOYSA-N

InChi: InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 83.3 mg/mL (263.83 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

In CHO cells stably expressing human A2AR, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM in the presense of 0.1, 1 and 10 μM adenosine, respectively.

In Vivo:

Blockade of A2AR signaling with AZD4635 could reduce tumor burden and enhance antitumor immunity.

References:

1. Alexandra Borodovsky, et al. Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5580.

Products are for research use only. Not for human use.